Fulcrum therapeutics reports recent business highlights and fourth quarter and full year 2020 financial results

– company on track to present data from phase 2b redux4 trial with losmapimod in facioscapulohumeral muscular dystrophy (fshd) in late-2q 2021 –

FULC Ratings Summary

FULC Quant Ranking